^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:cyclophosphamide (Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2 Negative Breast Cancer:…Invasive Breast Cancer…SYSTEMIC THERAPY REGIMENS FOR RECURRENT OR STAGE (IV) M1 DISEASE…HER2-Negative…Other Recommended Regimens…Cyclophosphamide
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

    Excerpt:
    ...- HER2/neu-negative tumor by IHC o If 2+ or in the indeterminate range, further testing of HER2/neu overexpression by fluorescent in situ hybridization (FISH) is required...
    Trial ID:
    NCT00499083
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    T-Cell Therapy for Advanced Breast Cancer

    Excerpt:
    ...- HER2 negative (in cases of mixed HER2 results, the most recent pathology results considered reflective of the active cancer will be considered)...
    Trial ID:
    NCT02792114
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

    Excerpt:
    ...The expression of HER-2 is negative by immunohistochemistry (IHC)....
    Trial ID:
    NCT05302336
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Comparative pharmacokinetics study (study to know the amount of study drug (cyclophosphamide) in your blood at specified time points – to understand “what body does to this study drug) of two products of cyclophosphamide powder for oral solution and Cyclophosphamide Tablets 50 mg in adult patients with breast cancer

    Excerpt:
    ...Participant must have of HER2 negative, ER/PR positive or negative breast cancer [as defined by American Society for Clinical Oncology (ASCO)- College of American Pathologists (CAP) guidelines] confirmed by local laboratory performed on primary tumor and/or metastatic lesion.5. ...
    Trial ID:
    2021-004897-77